Stephens Inc. AR Acquires 1,952 Shares of Sanara MedTech Inc. $SMTI

Stephens Inc. AR grew its position in shares of Sanara MedTech Inc. (NASDAQ:SMTI) by 18.0% during the second quarter, according to its most recent filing with the SEC. The firm owned 12,794 shares of the company’s stock after acquiring an additional 1,952 shares during the period. Stephens Inc. AR owned about 0.14% of Sanara MedTech worth $363,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. MetLife Investment Management LLC purchased a new stake in shares of Sanara MedTech in the 1st quarter worth approximately $82,000. Rhumbline Advisers lifted its holdings in shares of Sanara MedTech by 14.9% during the 1st quarter. Rhumbline Advisers now owns 3,714 shares of the company’s stock valued at $115,000 after buying an additional 483 shares during the period. Nuveen LLC bought a new position in Sanara MedTech in the 1st quarter worth $326,000. Finally, Bank of New York Mellon Corp increased its stake in Sanara MedTech by 6.3% in the 1st quarter. Bank of New York Mellon Corp now owns 13,880 shares of the company’s stock worth $428,000 after buying an additional 826 shares in the last quarter. Hedge funds and other institutional investors own 8.10% of the company’s stock.

Sanara MedTech Stock Up 3.3%

Sanara MedTech stock opened at $31.08 on Monday. The company has a debt-to-equity ratio of 1.25, a current ratio of 2.26 and a quick ratio of 2.03. The stock has a market capitalization of $276.61 million, a price-to-earnings ratio of -26.79 and a beta of 1.21. Sanara MedTech Inc. has a 1-year low of $23.53 and a 1-year high of $39.08. The business has a fifty day moving average price of $32.26 and a 200-day moving average price of $30.18.

Sanara MedTech (NASDAQ:SMTI) last announced its quarterly earnings data on Wednesday, August 13th. The company reported ($0.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.10. The firm had revenue of $25.83 million for the quarter, compared to analyst estimates of $25.15 million. Sanara MedTech had a negative net margin of 10.22% and a negative return on equity of 26.43%. Equities research analysts forecast that Sanara MedTech Inc. will post -1.1 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have recently weighed in on SMTI shares. HC Wainwright raised their price objective on Sanara MedTech from $53.00 to $54.00 and gave the company a “buy” rating in a research report on Monday, August 18th. Weiss Ratings reissued a “sell (e+)” rating on shares of Sanara MedTech in a research note on Saturday. Finally, Wall Street Zen raised shares of Sanara MedTech from a “hold” rating to a “buy” rating in a research note on Saturday, September 13th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $50.00.

Sanara MedTech Profile

Sanara MedTech Inc, a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers.